StockNews.com Begins Coverage on Ekso Bionics (NASDAQ:EKSO)

Equities researchers at StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note issued to investors on Sunday. The firm set a “hold” rating on the stock.

Other equities analysts have also issued reports about the company. HC Wainwright decreased their target price on Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th. Lake Street Capital decreased their price objective on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a report on Tuesday, October 29th.

Ekso Bionics Stock Down 6.0 %

Shares of NASDAQ EKSO opened at $0.61 on Friday. Ekso Bionics has a 1 year low of $0.50 and a 1 year high of $3.13. The firm’s 50-day moving average is $0.76 and its 200-day moving average is $0.98. The company has a current ratio of 2.81, a quick ratio of 2.14 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $13.42 million, a PE ratio of -0.94 and a beta of 1.43.

Ekso Bionics (NASDAQ:EKSO) last released its earnings results on Monday, October 28th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The business had revenue of $4.13 million for the quarter, compared to analyst estimates of $6.00 million. During the same period in the prior year, the firm posted ($0.24) EPS. Equities analysts expect that Ekso Bionics will post -0.48 EPS for the current year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.